Listen as Kat Rosqueta joins Denis Hadjiliadis of the Perelman School of Medicine at Penn and Arthur Caplan of NYU’s Langone Medical Center to discuss the Cystic Fibrosis Foundation decision to sell its rights in a drug for the rare lung disease for $3.3 billion. Read the article and listen to the podcast here.